0000000001081179

AUTHOR

Christoph Maintz

showing 2 related works from this author

Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.

2010

Background: This prospective observational study in typical community-based outpatient clinics evaluated the efficacy and toxicity of weekly and biweekly irinotecan-based chemotherapies and their compatibility depending on age. Methods: 601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecanbased therapy were regularly analyzed for response and toxicity until the end of therapy. Results: The median age was 65 (28–87) years, approximately one-third of the patients were ≥70 years old. Of all patients, 405 were treated weekly and 68 biweekly. Median overall survival (OS) for first-line therapy was 26.5 months for the <70-year-old patients …

OncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinAntineoplastic Combined Chemotherapy ProtocolsOutpatient clinicProspective StudiesAged 80 and overClinical Trials as TopicAge FactorsHematologyGeneral MedicineMiddle AgedCombined Modality TherapyTumor BurdenSurvival RateTreatment OutcomeOncologyChemotherapy AdjuvantDisease ProgressionFemaleFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyCombination therapyDrug-Related Side Effects and Adverse ReactionsMedizinische Fakultät -ohne weitere Spezifikation--AdenocarcinomaIrinotecanDrug Administration ScheduleAdvanced colorectal cancerInternal medicinemedicineHumansddc:610AgedNeoplasm StagingChemotherapybusiness.industrymedicine.diseaseClinical trialIrinotecanObservational studyCamptothecinbusinessOnkologie
researchProduct

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germa…

2021

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had pre…

MaleOncologymedicine.medical_specialtyEndocrinology Diabetes and Metabolismchromogranin AMedizindiarrheacarcinoid syndromeOctreotideAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsPeptides CyclicArticleflushing03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeGermanyInternal medicineOutcome Assessment Health CareInternal MedicinemedicineClinical endpointHumansAgedMalignant Carcinoid Syndromebiologybusiness.industryChromogranin AGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumorsquality of lifeTolerabilityAustria030220 oncology & carcinogenesisbiology.proteinFemaleObservational studySomatostatinbusinessCarcinoid syndromemedicine.drugExperimental and Clinical Endocrinology &amp; Diabetes
researchProduct